Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia; Rigel Pharmaceuticals, ...
Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights ...
Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH ...
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...
The global burden of chronic lymphocytic leukemia (CLL) has decreased over the past 30 years, according to a new analysis. However, the authors of the new report published in Cancer Control noted that ...
Real-world data on usage of the tyrosine kinase inhibitor nintedanib (Ofev; Boehringer Ingelheim) suggest there is ...
Elevated CTI values correlate with higher odds of RA, even after adjusting for demographic, socioeconomic, lifestyle, and clinical factors. Elevated levels of a combined biomarker integrating CRP, ...
The study shows a significant drop in CRS and ICANS risk 15 days after liso-cel infusion, supporting reduced monitoring ...
Ryan Haumschild, PharmD, discusses overcoming barriers to cancer care access, emphasizing the role of pharmacy in improving access and affordability. Novel therapies have revolutionized the cancer ...
NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...
Acoramidis significantly reduced all-cause mortality in both wild-type and variant amyloid cardiomyopathy through 42 months of the ATTRibute-CM study. The study demonstrated consistent efficacy in ...
Nearly 60% of patients with high-grade serous ovarian cancer (HGSOC) had a qualifying index surgery during which an opportunistic salpingectomy could have been performed, often an average of 3 decades ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results